D-Mannose is a natural monosaccharide often used as a dietary supplement to prevent and treat urinary tract infections (UTIs) due to its ability to inhibit bacterial adhesion to the bladder walls. Despite its benefits, D-Mannose can face challenges in terms of bioavailability and duration of effect.
Benefits of D-Mannose
D-Mannose is particularly effective in preventing recurrent UTIs in susceptible individuals. It works by specifically binding to the fimbriae of certain bacteria like E. coli, preventing them from adhering to the urinary tract walls and facilitating their elimination through urine.
D-Mannose MATRIS® RETARD GP: An Advanced Solution by IPS
IPS International Products & Services S.r.l. has developed D-Mannose MATRIS® RETARD GP, a supplement that uses advanced technology to significantly improve the absorption and duration of D-Mannose’s effect. MATRIS® RETARD GP technology ensures prolonged release of the active ingredient up to 8 hours and provides gastro-protection that preserves the integrity of the active ingredient during gastric transit. Less than 15% of the active ingredient is released in the first 2 hours at acidic pH, ensuring consistent and prolonged effectiveness in the intestinal tract at neutral pH.
Efficacy Supported by Studies
Recent preclinical studies and SEM (Scanning Electron Microscopy) analyses have highlighted the unique properties of MATRIS® technology. This technology alters the absorption kinetics of the nutraceutical ingredients, extending their half-life and significantly reducing inflammation and sensitization levels in the gastric and intestinal areas. These results demonstrate that the MATRIS® RETARD technology can offer enhanced efficacy compared to standard formulations.
Formulations and Applications
D-Mannose MATRIS® RETARD GP is suitable for implementation in various dosage forms, such as tablets, sachets, stick packs, capsules, and vials. This versatility effectively meets diverse market needs. For applications requiring direct compression, IPS also offers SmarTTabs®, which preserves the original active release profile of the bulk product, thus ensuring the integrity and efficacy of the active ingredient.
Conclusion
D-Mannose MATRIS® RETARD GP by IPS represents a significant advancement in the nutraceutical supplement field, offering an effective solution to overcome the challenges associated with the use of D-Mannose. IPS’s commitment to research and development continues to set new standards of excellence in the nutraceutical industry, improving patient lives with cutting-edge and scientifically validated products.
Note: This article is provided for informational purposes only and does not substitute for professional medical advice.
